KLRK1 and acute myeloid leukemia: Furthermore, CAR T therapy utilizing NKG2D-based [10] and anti-Lewis-Y (LeY) CAR T cells [11] have been evaluated in clinical phase I studies to target NKG2D ligands and LeY antigen expressing AML blasts.